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Although the sodium channel blocker, mexiletine, is the ﬁrst choice drug in myotonia, some myotonic
patients remain unsatisﬁed due to contraindications, lack of tolerability, or incomplete response. More
therapeutic options are thus needed for myotonic patients, which require clinical trials based on solid
preclinical data. In previous structure-activity relationship studies, we identiﬁed two newly-synthesized
derivatives of tocainide, To040 and To042, with greatly enhanced potency and use-dependent behavior
in inhibiting sodium currents in frog skeletal muscle ﬁbers. The current study was performed to verify
their potential as antimyotonic agents. Patch-clamp experiments show that both compounds, especially
To042, are greatly more potent and use-dependent blockers of human skeletal muscle hNav1.4 channels
compared to tocainide and mexiletine. Reduced effects on F1586C hNav1.4 mutant suggest that the
compounds bind to the local anesthetic receptor, but that the increased hindrance and lipophilia of the
N-substituent may further strengthen drug-receptor interaction and use-dependence. Compared to
mexiletine, To042 was 120 times more potent to block hNav1.4 channels in a myotonia-like cellular
condition and 100 times more potent to improve muscle stiffness in vivo in a previously-validated rat
model of myotonia. To explore toxicological proﬁle, To042 was tested on hERG potassium currents, motor
coordination using rotarod, and C2C12 cell line for cytotoxicity. All these experiments suggest a satis-
factory therapeutic index for To042. This study shows that, owing to a huge use-dependent block of
sodium channels, To042 is a promising candidate drug for myotonia and possibly other membrane
excitability disorders, warranting further preclinical and human studies.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Blockers of voltage-gated sodium channels are clinically used in
a number of disorders of plasma membrane excitability, including
cardiac arrhythmias, epileptic seizures, pain, and myotonia (Imbrici
et al., 2016). Many sodium channel blockers bind to the localnthracene-9-carboxylic acid;
, Department of Biomedical
ldo Moro, Polyclinic, Piazza
F. Desaphy).
Ltd. This is an open access article uanesthetics receptor located within the pore of the channel
(Ragsdale et al., 1994, 1996). This receptor is highly conserved
among sodium channel subtypes, thereby allowing most blockers
to exert similar block of sodium channels expressed in central and
peripheral neurons, cardiomyocytes and skeletal muscle ﬁbers
(England and de Groot, 2009). In most cases, the safety of these
drugs relies on their ability to block sodium channels in a
frequency-dependent manner, allowing a selective inhibition of
over-excited cells while sparing the healthy organs. Recently, more
selective blockers have been identiﬁed, especially for the peripheral
nerve Nav1.7 and Nav1.8 subtypes, and some of them are being
evaluated in clinical studies for the treatment of chronic pain (De
Lera Ruiz and Kraus, 2015; Theile and Cummins, 2011).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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stiffness due to sarcolemma hyper-excitability, which can be
painful and badly interferewith dailymotor activities and quality of
life (Statland et al., 2014; Suetterlin et al., 2014). A randomized
controlled clinical trial recently demonstrated the efﬁcacy of the
antiarrhythmic drug mexiletine in myotonia (Hoffman and
Kaminski, 2012; Statland et al., 2012). Consequently, mexiletine
received orphan drug designation for treatment of myotonic dis-
orders by F.D.A. and E.M.A. (U.S. Food and Drug Administration,
2010; European Medicines Agency, 2013a; 2013b, 2014). By block-
ing skeletal muscle Nav1.4 sodium channels in a use-dependent
manner, the drug inhibits the myotonic discharges of action po-
tentials and favors muscle relaxation (De Luca et al., 1997; Desaphy
et al., 1999). The drug also alleviates the transitory muscle weak-
ness associated with recessive myotonia congenita due to chloride
channel ClC-1 mutations (Lo Monaco et al., 2015). Nevertheless, a
number of myotonic patients obtain little beneﬁts from mexiletine
due to contraindications, side effects, lack of tolerability, or lack of
response (Matthews and Hanna, 2014; Suetterlin et al., 2015). In
addition, mexiletine distribution has been interrupted by the
manufacturer in a number of countries, making very difﬁcult access
to the drug. In sodium channel-related myotonias, unsatisfactory
response to mexiletine may stem from a reduced afﬁnity of the
mutated channel to the drug, and other sodium channel blockers,
like ﬂecainide, may be successful in such cases (Desaphy et al.,
2004, 2013c; 2016). The other orally-available lidocaine analogue,
tocainide, has been also used in myotonia (Streib, 1986, 1987), but
was associated with an elevated incidence of serious adverse re-
actions and discontinued in many countries. There is thus a general
opinion that more therapeutic options are needed for myotonic
patients, and that clinical trials based on solid preclinical data are
urgently needed (Matthews and Hanna, 2014).
Searching for other useful antimyotonic drugs, we recently
developed a pharmacologically-induced model of myotonia in the
rat and investigated a number of marketed sodium channel
blockers (Desaphy et al., 2013b, 2014). We found that the anti-
myotonic activity of drugs in vivo was closely parallel to the in vitro
inhibition of sodium currents elicited by high-frequency voltage-
clamp protocols in mammalian cells transfected with hNav1.4
cDNA. Beside the study of marketed drugs, we also explored the
possibility to increase potency and use-dependent behavior
through chemical optimization of mexiletine and tocainide in a
series of SAR studies (De Bellis et al., 2013; De Luca et al., 2000,
2003a; 2003b, 2012). We have identiﬁed beta-proline derivatives
of tocainide with a 10-fold increase in potency and use dependence
for blockade of sodium channels in frog muscle ﬁbers (Catalano
et al., 2008). One of these compounds, namely NeP1 or To10
(Fig.1), was 10 timesmore potent than tocainide in blocking human
sodium channels and showed considerable analgesic activity in
animal models of neuropathic pain (Ghelardini et al., 2010). Lately,
on the basis of a 3D-QSAR study, new chemical maneuvers allowed
to obtain two promising compounds 100 times more potent than
tocainide, namely To040 and To042 (Carrieri et al., 2009; Muraglia
et al., 2014) (Fig. 1).
The aim of the present study was to verify the potency of these
two new compounds on the human Nav1.4 isoform expressed in
mammalian cell line, obtain information about the molecular
binding site, and test their antimyotonic activity in vivo in the rat
model of myotonia (Desaphy et al., 2013b, 2014). Beside efﬁcacy,
we also performed experiments to explore the toxicological pro-
ﬁle, including effects on hERG potassium channels and cytotox-
icity. The results indicate To042 as a promising candidate drug for
myotonia and, possibly, other plasma membrane excitability dis-
orders, warranting further preclinical studies and hopefully clinical
trials.2. Materials and methods
2.1. Patch-clamp recording in HEK293 or tSA201 cell lines
Sodium or potassium currents were recorded using thewhole-cell
patch-clamp conﬁguration in Human Embryonic Kidney 293
(HEK293) cells or tSA201cells (aderivativeofHEK293cells) expressing
thehumanskeletalmuscle voltage-gated (hNav1.4) sodiumchannelor
the human Ether-a-go-go Related Gene (hERG) potassium channel.
Permanent transfection of HEK293 cells with wild-type hNav1.4
channel or its F1586Cmutant has beenpreviously described (Desaphy
et al., 2009, 2012). Transient transfection of tSA201 cells with 8 mg of
pcDNA3.1 expression vector containing the coding region of hERG
channel (a generous gift fromprof. Valeria Casavola, University of Bari,
Italy; originally from prof. E. Ficker, MetroHealth Medical Center, Case
Western Reserve University, Cleveland, OH) and 1 mg of a vector
encoding the CD8 gene reporter was performed using the calcium-
phosphate co-precipitation method (Desaphy et al., 2001). Only cells
decoratedwithmicro-beads coatedwith anti-CD8antibodywereused
for patch-clamp 24 at 48 h after transfection.
Patch-clamp recordings were performed at ambient tempera-
ture (20e22 C) using an Axopatch 1D ampliﬁer (Axon Instruments,
Molecular Devices, Sunnyvale, CA). Voltage clamp protocols and
data acquisition were obtained with pClamp 10.2 software (Axon
Instr.), through a 12-bit A-D/D-A interface (Digidata 1440, Axon
Instr.). Pipettes were fabricated from Corning 7052 glass capillaries
(Garner Glass, Claremont, CA, USA) using a vertical PP-82 puller
(Narishige, Tokyo, Japan), to obtain tip resistance in between 1.5
and 3.5 MU. Currents were low-pass ﬁltered at 2 kHz (3 dB) and
digitized at 10e20 kHz. Five minutes after establishing the whole-
cell conﬁguration, sodium or potassium currents were recorded
using speciﬁc voltage-clamp protocols described in the Results
section. Data were analyzed off-line using Clampﬁt 10.2 and Sig-
maPlot 10.0 (Systat Software GmbH, Erkrath, Germany).
2.2. In vivo evaluation of the antimyotonic activity of To042
Animal housing and experiments were performed in accordance
with the Italian Guidelines for the use of laboratory animals, which
conforms to the European Union Directive for the protection of
experimental animals (2011/63/EU), and received approval from
the Animal Experimentation Ethic Committee of the University of
Bari (CESA prot. 7/12) and Italian Health Department (Decreto n. 91/
2013-B). All efforts were made to minimize animal suffering and to
reduce the number of animals used. Twelve adult Wistar rats (body
weight: 350e500 g; Charles River Laboratories, Calco, Italy) were
individually housed and received water and food ad libitum. Ex-
periments were performed in 3e4 rats simultaneously as previ-
ously described (Desaphy et al., 2013b, 2014). Brieﬂy, myotonia
conditionwas induced in the rats by i.p. injection of 30 mg/kg body
weight of 9-anthracene-carboxylic acid (9-AC), a potent blocker of
skeletal muscle ClC-1 chloride channels. A few minutes after 9-AC
injection, animals constantly show a manifest muscular stiffness
and difﬁculties to move, with no noticeable side effects (Desaphy
et al., 2013b). The myotonia was quantiﬁed by measuring the
time of righting reﬂex (TRR), that is time needed by the rat to turn
back on its four limbs from the supine position. Tenminutes after 9-
AC injection, the rats were administrated an oral dose of drug
(mexiletine or To042) or vehicle saline solution using an esopha-
geal cannula. The TRRwas determined 10min before 9-AC injection
and 30, 60, 120 and 180 min after 9-AC. At each time point, the TRR
value was calculated as the mean of 7 determinations, repeated at
1-min intervals to prevent the warm-up phenomenon. For each
drug dose, the experiments were repeated at least 3 times in
different rats, and experimental data are given as the mean ± S.E.M.
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Fig. 1. Chemical structures of tocainide and explorative compounds. The compound To10 is a benzyl-N-substituted b-proline derivative of tocainide (known also as NeP1, Ghelardini
et al., 2010). In To040, the b-proline cycle was eliminated. In To042, the benzyl moiety was substituted for by a naphthalene group (Muraglia et al., 2014).
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Thewell-established rotarod test was used to exclude undesired
CNS effects of To042. Twelve male Wistar rats (Charles River Lab.),
weighting 150e250 g, were trained daily for 5 days on the rotarod
(Panlab-Harvard Apparatus, Cornella, Spain) to make the animals
familiar with handling, oral administration using esophageal can-
nula, and rotarod hardware. The daily procedure consisted in 4
trials on the rotarod, accelerating from 4 to 40 rpm in 2 min, run
10min before, and 10, 30, and 100min after vehicle (sterile distilled
water) administration (time 0). The rotarod performance was
evaluated at each time point as the time length the rat was able to
stay on the rotarod. After the training period, one half (six) rats
were randomly assigned to drug group, receiving 3 mg/kg To042
per os at time 0. The test was repeated 5 times a week. Drug dose
was increased to 10 mg/kg for another week, and to 30 mg/kg for
the last week. Performance value was calculated at each time point
as the mean ± SEM from 5 trials (days) measured in 6 rats.2.4. In vitro cytotoxicity studies
Murine C2C12 skeletal muscle cells were cultured and main-
tained at 37 C in 5% CO2/95% O2 in DMEM containing 10% fetal
bovine serum (FBS) and 1% penicillin and streptomycin. For cell
viability tests, cells at 70% conﬂuencewere re-suspended in 96-well
cultures at a density of ~12.000e13000 cells per well in culture
medium. After 18 h, they were incubated with tocainide or To042
for 6 h. Stock solutions of To042 were prepared by dissolving the
compound in DMEM containing <0.1% dimethylsulfoxide (DMSO).
DMSO at the concentration used for dilution had no effect on cell
viability. Tocainide was readily soluble in DMEM. Fresh stock so-
lutions were made daily and diluted as required. One hour before
absorbance lecture, 10 ml of Cell Counting Kit-8 pure solution (CCK-
8 Alexis Biochemicals) was added into each well. The CCK-8 solu-
tion contains the monosodium salt of [2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazo-
lium (WST-8), which is reduced by cellular dehydrogenases to give
a yellow colored product (formazan) absorbing at 450 nm. The
quantity of formazan dye is directly proportional to the number of
viable cells. Absorbancewas measured at 450 nmwith amicroplate
spectrophotometer (Victor V31420-40, PerkinElmer). Cell viability
is expressed as percent with respect to cell treated with vehicle
alone (0.1% DMSO), after proper subtraction of blank absorbance.
The data are expressed as mean ± SEM, and differences are
considered signiﬁcant for p < 0.05 using unpaired Student's t-test.2.5. Drugs and solutions
For sodium current recordings, the pipette solution contained
(in mM): CsF 120, CsCl 10, NaCl 10, EGTA 5, HEPES 5; and was
adjusted to pH ¼ 7.2 with CsOH. The extracellular bath solution
contained (in mM): NaCl 150, KCl 4, CaCl2 2, MgCl2 1, HEPES 5,
glucose 5; and was adjusted to pH 7.4 with NaOH. For hERG po-
tassium current recordings, the pipette solution contained (in mM)
KCl 130, MgCl2 1, MgATP 5, EGTA 5, HEPES 10; and was adjusted to
pH 7.2 with KOH. The extracellular bath solution contained (in
mM): NaCl 123, KCl 4, CaCl2 2, MgCl2 1, 25 NaHCO3 25, NaH2PO4 2,
HEPES 5; and was adjusted to pH 7.4 with NaOH. For patch-clamp
experiments, To040, To042, and mexiletine were solubilized in
the bath solution supplemented with 0.2% DMSO to obtain the
desired concentration. No effect of 0.2% DMSO was observed on
sodium or potassium currents. The patched cell was continuously
exposed to a stream of control or drug-supplemented bath solution
ﬂowing out by gravity from a plastic capillary positioned close to
the cell.
For in vivo experiments, the solution of anthracene-9-carboxylic
acid (2.4 g/l 9-AC) was prepared each day in sterile water supple-
mented with 0.3% bicarbonate and the volume for intraperitoneal
injection was adjusted to obtain 30 mg/kg body weight (Desaphy
et al., 2013b, 2014). The exploratory drugs were solubilized daily
in physiological 0.9% NaCl saline at the desired dose for oral
administration in rats with an esophageal cannula (ﬁnal volume of
about 1 ml).
All drugs and chemicals were purchased from Sigma-Aldrich,
whereas To040 and To042 were synthesized in our laboratories
as salts, as previously described (Catalano et al., 2008; Muraglia
et al., 2014).3. Results
3.1. Dose- and use-dependent inhibition of human Nav1.4 channels
by tocainide derivatives
Tocainide derivatives were tested on hNav1.4 channels perma-
nently expressed in HEK293 cells using whole-cell patch-clamp. To
allow comparison with other previously-tested drugs, including
tocainide, To10, and mexiletine, the stimulation protocol consisted
in holding the cells at 120 mV and eliciting sodium currents by
depolarizing cells at 30 mV for 25 ms. The stimulation frequency
was ﬁrst ﬁxed at 0.1 Hz to determine tonic block, and then
increased to 10 Hz to determine phasic block (Desaphy et al., 2009,
2013a,b,c). Representative effects of 30 mM To040 and To042 are
M. De Bellis et al. / Neuropharmacology 113 (2017) 206e216 209shown in Fig. 2A. The concentration-response relationships ob-
tained on hNav1.4 currents are shown in Fig. 2B. They were ﬁtted
with the standard Hill equation (1):
IDRUG=ICTRL ¼ 1
.
ð1þ ½DRUG=IC50Þnh; (1)
where IC50 (mM) is the half-maximum inhibitory concentration and
nH is the logistic slope factor; ﬁt values are reported in Table 1. Both
the new tocainide derivatives exerted a huge dose- and use-
dependent block of sodium currents, the most potent being
To042. The block of sodium channels was fully reversed upon drug
washout (not shown). In Fig. 2C are shown the IC50 values for To040
and To042, compared to previously published values for tocainide,
To10, and mexiletine. Tocainide is the less potent blocker, followed
by mexiletine. Both these drugs display antimyotonic activity in
patients; while mexiletine has recently received orphan designa-
tion in myotonic syndromes, tocainide has been withdrawn
because of side effects. The benzyl-b-proline tocainide derivative,
To10 (also called NeP1), showed a signiﬁcant improvement of so-
dium channel inhibition and analgesic activity in animal models
(Ghelardini et al., 2010; De Luca et al., 2012). In this study, the new
To040 compound showed IC50 values very similar to To10, while
To042 compound further improved both tonic and phasic block.
Compared to the reference antimyotonic drug, mexiletine, the IC50
values of To042 were reduced 20- and 30-fold at 0.1 and 10 Hz
frequency stimulations, respectively.Fig. 2. Concentration-dependent effects of tocainide derivatives on hNav1.4 channels. (A)
HEK293 cells at steady-state before (CTRL) and during application of 30 mM To040 or To042 a
To040 and To042 on WT hNav1.4 currents at 0.1 and 10 Hz. Each experimental point is the
equation (1) reported in the text, and ﬁt parameter values are reported in Table 1 (C) bargr
tocainide (Toc).3.2. The tocainide analogues bind to the local anesthetic receptor
Many use-dependent sodium channel blockers bind to the local
anesthetic (LA) receptor located within the ion conducting pore in
the sixth transmembrane segment of domain IV of the Nav protein
(Ragsdale et al., 1994, 1996). In particular, the p-cation interaction
between the charged amine group of LA-like drugs and the aro-
matic moiety of F1586 residue in hNav1.4 is critical for drug binding
and channel use-dependent inhibition (Desaphy et al., 2012; Pless
et al., 2011). Accordingly, the F1586C mutation in hNav1.4 fully
zeroed the use-dependence of channel block by mexiletine
(Desaphy et al., 2009, 2012). To verify whether the two tocainide
derivatives also bind to the LA receptor, the compoundswere tested
on the F1586C hNav1.4 mutant channel. Representative F1586C
current traces recorded before and after 30 mMdrug application are
shown in Fig. 3A; The concentration-response relationships ob-
tained on WT channels are shown in Fig. 3B, and the ﬁt parameters
are reported in Table 1. Compared to wild-type, both tonic and
phasic blocks were greatly impaired by the F1586C mutation (~2-
and ~15-fold reduction, respectively); the 0.1-to-10 Hz IC50 ratio
was greatly reduced, but use-dependence was not completely
zeroed.3.3. Block of hNav1.4 channels by To042 in myotonic-like
conditions
The myotonic condition is characterized by action potential
ﬁring at elevated frequencies ranging from tens to hundreds of Hz.
To test the most potent Toc derivative, To042, on hNav1.4 channelsRepresentative traces of wild-type hNav1.4 sodium currents recorded in transfected
t 0.1 Hz and 10 Hz frequency stimulations. (B) Concentration-response relationships of
mean ± S.E.M. of at least 3 cells. The relationships were ﬁt to the ﬁrst-order binding
aph shows IC50 values calculated as in B for To042, To040, To10, mexiletine (Mex), and
Table 1
Fit parameters of concentration-response relationships for Tocainide derivatives on wild-type and F1586C hNav1.4 channels.
Tonic block (0.1 Hz) Phasic block (10 Hz) 0.1-to-10 Hz ratio
IC50 (mM) nH IC50 (mM) nH
hNav1.4 e WT
To040 79 ± 17 1.2 ± 0.3 4.2 ± 0.8 0.8 ± 0.1 18.8
To042 12 ± 1 1.3 ± 0.1 0.81 ± 0.06 0.8 ± 0.1 14.8
To10a 67 ± 5 0.9 ± 0.1 4.9 ± 0.3 1.1 ± 0.1 13.7
Tocainidea 699 ± 69 1.0 ± 0.1 182 ± 24 1.1 ± 0.2 3.8
Mexiletineb 246 ± 15 0.9 ± 0.1 24 ± 2 0.8 ± 0.1 10.3
hNav1.4 - F1586C
To040 137 ± 9 1.1 ± 0.1 62 ± 4 1.0 ± 0.1 2.2
To042 44 ± 4 1.7 ± 0.0 14 ± 2 1.2 ± 0.2 3.1
Mexiletineb 1340 ± 72 1.1 ± 0.1 1089 ± 181 1.0 ± 0.2 1.2
Parameter values were determined from the ﬁt of concentrationeresponse curves shown in Figs. 2 and 3 with the standard Hill equation (1). The values are given together
with the SE of the ﬁt.
a From Ghelardini et al., 2010.
b From Desaphy et al., 2012.
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protocol consisting in depolarizing the cells from a holding po-
tential of 90 mV (close the resting membrane potential of muscle
ﬁbers), and 5 ms-long depolarization steps applied at the stimu-
lation frequency of 50 Hz (Desaphy et al., 2014, 2016). In absence of
drug, such a stimulation induced a frequency-dependent, ~30%
reduction of sodium currents (labeled UDB-C in Fig. 4A). In pres-
ence of 0.1 mM To042, a tonic block (TB) was measured at the
stimulation frequency of 0.1 Hz, and a further use-dependent block
(UDB-D) was measured at 50 Hz. Fig. 4B illustrates the averaged
time course of hNav1.4 peak current reduction observed in absence
(UDB-C) and presence (UDB-D) of 0.1 mM To042 (n¼ 7). To evaluateFig. 3. Concentration-dependent effects of tocainide derivatives on F1586C hNav1.4 chann
transfected HEK293 cells at steady-state before (CTRL) and during application of 30 mM To
relationships of To040 and To042 on WT hNav1.4 currents at 0.1 and 10 Hz. Each experim
ﬁrst-order binding equation (1) reported in the text, and ﬁt parameter values are reporte
mexiletine (Mex).the effect strictly related to drug, we subtracted UDB-C fromUDB-D
to obtain UDB and then add TB. The time course of TB þ UDB was
calculated at various To042 concentrations and reported in Fig. 4C,
while the TB þ UDB values were reported as a function of drug
concentration and compared to mexiletine in Fig. 4D. The re-
lationships were ﬁt with equation (2):
TBþ UDB ¼ 100
.
ð1þ ½DRUG=IC50Þnh; (2)
and ﬁt parameters are reported in Table 2. In a myotonia-like
condition, the tocainide derivative was 120 times more potentel mutant. (A). Representative traces of F1586C hNav1.4 sodium currents recorded in
040 or To042 at 0.1 Hz and 10 Hz frequency stimulations. (B) Concentration-response
ental point is the mean ± S.E.M. of at least 3 cells. The relationships were ﬁt to the
d in Table 1 (C) bargraph shows IC50 values calculated as in B for To042, To040, and
Fig. 4. Effects of tocainide derivatives on hNav1.4 channels in a myotonia-like condition. (A) Representative traces of wild-type hNav1.4 sodium currents recorded in transfected
HEK293 cells at steady-state before (CTRL) and during application of 0.1 mM To042. The cell was depolarized to 30 mV for 5 ms (as an action potential duration) from a holding
potential of 90 mV (close to the resting membrane potential of skeletal muscle ﬁbers) at 0.1 and 50 Hz frequency stimulations (as during a myotonic run). In absence of drug, a use-
dependent reduction of sodium current developed to reach a steady-state, UDB-C. In presence of drug, the tonic block (TB) exerted by To042 was measured at 0.1 Hz stimulation,
while the use-dependent sodium current reduction (UDB-D) was measured at 50 Hz. (B) Time course of hNav1.4 sodium current reduction at 50 Hz in absence (UDB-C) and
presence (UDB-D) of 0.1 mM To042. The quantity of block directly attributable to the drug (TB þ UDB) was calculated by subtracting UDB-C to UDB-D and adding TB. (C)
Concentration-dependent inhibition of hNav1.4 channels by To042 as calculated in B. (D) Concentration-response relationships for To042 and mexiletine determined as in C. Each
point is the mean ± S.E.M. from at least 3 cells. The relationships were ﬁt to the ﬁrst-order binding equation (2) reported in the text and ﬁt parameter values are reported in Table 2.
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3.4. In vivo antimyotonic activity of To042 in the rat
The antimyotonic activity of To042 was assayed in vivo in a
previously validated rat model of pharmacologically-induced
myotonia congenita (Desaphy et al., 2013b, 2014). The intraperito-
neal injection of 30 mg/kg 9-anthracene carboxylic acid (9-AC), a
chloride channel blocker, mimics the genetic condition of myotonia
congenita due to chloride channel loss-of-function mutation.
Muscle stiffness, evaluated by measuring the time of righting reﬂex
(TRR), is increased 10 min after 9-AC injection, reaches a maximum
value after 30 min and then decreases gradually (Fig. 5A and B). An
antimyotonic drug is expected to reduce the TRR; the antimyotonic
effect of To042, orally-administrated 20 min after 9-AC injection,Table 2
Fit parameters of concentration- and dose-response relationships for To042 and
mexiletine for antimyotonic activity in vitro and in vivo.
In vitro In vivo
IC50 (mM) nH ED50 (mg/kg) nH Min (%)
To042 0.14 ± 0.02 0.9 ± 0.1 0.07 ± 0.02 1.2 ± 0.3 30.9 ± 4.4
Mexiletine 16.9 ± 2.4 1.2 ± 0.2 7.0 ± 0.02 1.2 ± 0.2 18.0 ± 7.3
Parameter values were determined from the ﬁt of concentratione and dose-
response relationships shown in Figs. 4 and 5 with standard Hill equations (1)
and (2), respectively. The values are given together with the SE of the ﬁt.was compared to vehicle (Fig. 5B). The Toc derivative exerted
antimyotonic activity at doses greater than 0.01mg/kg andwas able
to exert a ~70% reduction of TRR at doses greater than 0.3 mg/kg.
The dose-antimyotonic effect relationships were drawn for To042
and mexiletine and ﬁt with equation (3):
TRR ¼ Minþ ð100MinÞ
.h
1þ exp
.
ð½DRUG=ED50ÞnH
i
; (3)
where ED50 (mg/kg) is the half-maximum effective dose, nH is the
logistic slope factor, Min is the minimal TRR value, and (100-Min)
corresponds to the maximal effect. Fit parameters are reported in
Table 2. In vivo, To042 (ED50 ¼ 0.07 mg/kg) resulted 100-fold more
potent than mexiletine, although associated to a slightly reduced
efﬁcacy thanmexiletine (maximal TRR reduction of ~70% compared
to ~80% for Mex).
Although To042 was given orally and no data is available
regarding To042 bioavailability, we made an attempt to estimate
the free blood concentration corresponding to the ED50. The blood
volume of a rat can be estimated from body weight using a formula
determined experimentally by Lee and Blaufox (1985). For a rat
body weight ranging between 350 and 500 g, the estimated blood
volume range is [21.8e30.8] mL. The ED50 for To042was 0.07mg/kg
(Table 2), that is [0.025e0.035] mg To042 for [350e500] g rat body
weight. Assuming a 100% bioavailability, the blood concentration of
To042 would be thus [1.15e1.14] mg/L, corresponding to 3.3 mM
(free base MW ¼ 347.47). In humans, tocainide shows oral
Fig. 5. In vivo effects of tocainide derivatives in a rat model of myotonia. (A) Experi-
mental protocol. Myotonia was induced in the rat by intraperitoneal injection of
30 mg/kg 9-anthracene carboxylic acid (9-AC) at time zero. The drug was adminis-
trated by os 20 min after 9-AC injection. The time of righting reﬂex (TRR) was
measured at various before and after 9AC injection, as a measure of muscle stiffness.
(B) Time course of the antimyotonic activity of To042 at different doses. The TRR was
normalized with respect to that measured at 10 min time point. Experimental points
are the means ± S.E.M. from at least 3 rats. (C) Dose-response relationship of To042,
compared to the one of mexiletine, calculated as in B at 30 min time point. Each
experimental point is the mean ± S.E.M. from at least 3 rats. The relationships were ﬁt
to the ﬁrst-order binding equation (3) reported in the text, and ﬁt parameter values are
reported in Table 2.
M. De Bellis et al. / Neuropharmacology 113 (2017) 206e216212bioavailability of ~100% and is ~50% plasma protein bound (Lalka
et al., 1976). Assuming a similar behavior of To042 in rats, the free
To042 blood concentration corresponding to the ED50 would be
1.7 mM. However, binding afﬁnity of To042 to human and rat serum
albumin in vitro is by far greater than that of tocainide, most likely
due to the elevated lipophilicity of the former (Pistolozzi et al.,
2014). In these in vitro experiments, the free portion of To042
was approximately 20 times lower than that of tocainide. Thus with
a further speculation, we may hypothesize that, at the dose of
0.07 mg/kg, the free To042 concentration in rat blood would be0.085 mM. This value is amazingly very close to the IC50 for use-
dependent inhibition of sodium channels (0.14 mM, Table 1).
3.5. Effects of To042 on cardiac hERG channels
It is well known that inhibition of the cardiac delayed rectiﬁer
current (IKr) and its cloned molecular counterpart, the human
Ether-a-go-go related gene (hERG) channel, mediates the life-
threatening QT interval prolonging effects of a wide range of clin-
ically used drugs, especially those containing hydrophobic groups
linked to a basic nitrogen (Durdagi et al., 2010; Kannankeril et al.,
2010). A number of sodium channel blockers have been proposed
to exert hERG channel blockade at clinically relevant concentra-
tions (Danielsson et al., 2003; Paul et al., 2001, 2002). Although the
Class Ib antiarrhythmic agents, mexiletine and lidocaine, have
comparatively low afﬁnity for IKr/hERG channels (Paul et al., 2002;
Wang et al., 1996), we veriﬁed whether To042 may exert signiﬁcant
hERG channel block in transfected tSA cells. We used a conven-
tional voltage protocol, consisting in successive 5-s voltage steps
applied every 18 s, ranging from 70 to þ70 mV, in 10-mV in-
crements, and followed by a 5-s step to 50 mV to elicit hERG tail
currents (Fig. 6A). Representative examples of hERG current fam-
ilies recorded before and after application of 10 mM To042 or
100 mM mexiletine are illustrated. Current-voltage relationships in
Fig. 6B show the dose-dependent effect of drugs on current
amplitude measured at the end of ﬁrst voltage step. Inhibition of
hERG currents by mexiletine was observed at concentrations
greater than 1 mM and was complete at 1 mM. Effect of To042
initiated at concentrations greater than 0.1 mM and was maximal at
100 mM. The concentration-response relationships were obtained
from hERG tail currents elicited at10 mV and ﬁtted with equation
(1) (Fig. 6C). The IC50 values were 42.8 ± 4.4 mM (nH ¼ 0.79 ± 0.07)
for mexiletine and 5.9 ± 1.4 mM (nH ¼ 0.77 ± 0.13) for To042.
3.6. Effects of To042 on rat motor coordination
In a recent study, the rotarod test was used to compare effects of
three drugs on motor coordination in adr mice, a genetic model of
myotonia congenita (Novak et al., 2015). The results showed that,
although the three drugs displayed similar antimyotonic activity in
the TRR test, one of these was not able to improve rotarod perfor-
mance, suggesting CNS toxic effects.
To exclude CNS toxicity of To042 in vivo, we evaluated rat motor
coordination and balance after oral drug administration using the
rotarod test in control rats. The rotarod performancewas calculated
as the time length the rat was able to stay on the rotarod, the speed
of which accelerated from 4 to 40 rpm in 2 min. The tocainide
derivative did not alter rat motor performance at dose up to 30 mg/
kg p.o. (Fig. 7).
Note that we did not perform the rotarod test in 9-AC treated
rats, because this would not add any important information
regarding drug toxicity.
3.7. Cytotoxicity
The safety of tocainide has been long questioned and its use
limited in some countries due to the undesirable cytotoxic effects.
We previously observed a reduction of HeLa and MRC-5 cell
viability with 100 mM tocainide (Ghelardini et al., 2010). Other local
anesthetic-like drugs have been shown to exert toxic effects on
skeletal muscle cells, both in vivo and in vitro (Foster and Carlson,
1980; Irwin et al., 2002; Hofmann et al., 2013). Although the exact
molecular mechanism for tocainide cytotoxicity is not clear yet, we
evaluated the ability of tocainide and To042 to affect viability of
murine C2C12 skeletal muscle cells. Cells were exposed for 6 h to
Fig. 6. Comparative effects on To042 and mexiletine on hERG potassium channel. (A) Representative traces of hERG potassium currents recorded in transfected tsA201 cells at
steady-state before (CTRL) and during application of 100 mMmexiletine (left panel) or 10 mM To042 (right panel). The cells were held at 70 mV and depolarized for 5 s to potentials
ranging from 70 to þ70 mV, applied in 10 mV increments. Tail currents were recorded at 50 mV. (B) Current-voltage relationships were drawn from steady-state current
amplitudes measured at the end of the 5 s-long test pulse, before and during application of various mexiletine (left panel) and To042 concentrations (right panel). Each experi-
mental relationship is the mean ± S.E.M. of at least 3 cells. (C) Concentration-response relationships drawn using tail current amplitudes measured at 50 mV after test depo-
larization at 10 mV. Each data point is the mean ± S.E.M. from at least 3 cells. The relationships were ﬁt to the ﬁrst-order binding equation (1) and ﬁt parameter values are reported
in the text.
M. De Bellis et al. / Neuropharmacology 113 (2017) 206e216 213increasing concentrations of drugs (Fig. 8). From 100 mM to 1 mM,
tocainide signiﬁcantly reduced cell viability by about 20%. The
tocainide derivative had no signiﬁcant effect up to 1 mM, and
induced a signiﬁcant reduction of cell viability between 10 and
100 mM; the reduction was less than 12% at 100 mM. These results
suggest that To042 is likely less myotoxic than tocainide; Impor-
tantly, 1 mM To042 produced no myotoxic effect, while inhibiting
more than 50% of hNav1.4 channels at 50 Hz stimulation
(IC50 ¼ 0.14 mM).4. Discussion
Through a series of previous SAR studies, we obtained two
tocainide analogues, namely To040 and To042, showing greatly
enhanced potency and use-dependent block of sodium currents
recorded in frog skeletal muscle ﬁbers (Carrieri et al., 2009; De Luca
et al., 2004, 2012; Muraglia et al., 2014; Talon et al., 2001). Here we
show that these two compounds are also very potent blockers of
human skeletal muscle voltage-gated sodium channels. Using a
holding potential of 120 mV, To040 appears 9 and 43 times more
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Fig. 7. Effects of To042 on rat motor coordination measured as the latency to fall from
the rotarod. Each data point is the mean ± S.E.M. from 6 rats.
M. De Bellis et al. / Neuropharmacology 113 (2017) 206e216214potent than tocainide in blocking hNav1.4 channels at 0.1 and
10 Hz, respectively. Yet, To040 showed very similar effects to those
of a benzylated beta-proline derivative of tocainide, namely To10 or
NeP1 (Ghelardini et al., 2010), indicating that the constriction of the
amine group in a rigid cycle does not necessarily affect the binding
of drugs to hNav1.4 channels. In contrast, with the introduction of a
naphthyl in place of the benzyl group, To042 appears more potent
than To10 and To040 on hNav1.4 channels at both stimulation
frequencies, indicating that increased hindrance and/or lipophilia
on the N moiety further improves the binding of the drug to the
channel. Thus To042 was 58 (0.1 Hz) and 225 (10 Hz) times more
potent than its parent compound tocainide and is, so far, the most
potent synthetic compound we found to block hNav1.4 channels,
being slightly more potent than lubeluzole (Desaphy et al., 2013a).
The impairment of F1586C mutant inhibition by To040 and
To042 compared to WT hNav1.4 demonstrates that Phe in position
1586 is involved in the binding of tocainide analogues to the
channel, as for other local anesthetic-like drugs (Desaphy et al.,
2012; Pless et al., 2011; Ragsdale et al., 1994, 1996). Nevertheless,
contrarily to mexiletine but similarly to lubeluzole, the use-
dependence was not fully zeroed by the mutation, suggesting
that the benzyl or naphthyl group in To040 or To042 may add a
third pharmacophoric interaction with the receptor that enhanceslavivruS lle
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Fig. 8. Citotoxic effects of tocainide and To042 on murine C2C12 cells, expressed as perce
mean ± SEM from 4 to 6 experiments. Statistical analysis was performed using unpaired Shigh-afﬁnity binding, as previously proposed for lubeluzole
(Desaphy et al., 2013a).
The huge potency and use-dependent behavior of To042make it
an interesting candidate for treatment of myotonia, a disease
characterized by high-frequency ﬁring of action potentials in
skeletal muscle ﬁbers. Our experiments in cell and animal models
of myotonia support this hypothesis. In transfected cells stimulated
in a myotonicelike manner, To042 blocked hNav1.4 currents with a
potency similar to lubeluzole and 120 times greater than mex-
iletine, the current drug of choice for myotonic syndromes
(Desaphy et al., 2014). In vivo, To042 was as potent as riluzole and
100 times more potent than mexiletine in reducing the time of
righting reﬂex in myotonic rats (Desaphy et al., 2014). Waiting for
more selective blockers of sodium channel subtypes, the use-
dependence behavior of sodium channel blockers is thought to
represent the basis for their selective action in pathological hyper-
excited tissues (England and de Groot, 2009). Thus, although To042
may not be selective for the skeletal muscle Nav1.4 channel, the
huge use-dependence of the compound, as expressed by the 0.1-to-
10 Hz ratio of IC50 values, suggests a likely selective action on the ill
organ, such as the myotonic muscle.
The toxicological studies suggest a satisfactory safety proﬁle for
To042. Mexiletine is reputedly a weak blocker of IKr/hERG currents
and shows little concern regarding the QT interval prolongation
(Suetterlin et al., 2015; Wang et al., 1996). In our study, the IC50 for
hERG inhibition by mexiletine was 2.5 greater than that for block-
ing hNav1.4 in the myotonia-like condition (43 versus 17 mM,
respectively). For To042, the ratio between hERG (6 mM) and
hNav1.4 (0.14 mM) inhibitions was greatly accentuated by 42 fold.
Thus, it is very likely that To042 would not exert any detrimental
effect on hERG potassium channels at clinically-relevant doses. In
rats, we observed no toxic effects of To042 in vivo either during the
myotonia assay or the rotarod assay. In addition, at the same con-
centrations able to block hNav1.4 channels, the compound exerted
little cytotoxic effects in vitro on murine muscle cells. These pre-
liminary observations will need to be conﬁrmed in further pre-
clinical studies before to test To042 in humans. For instance, a
particular attention should be given to blood dyscrasias and pul-
monary ﬁbrosis, which have been associated with tocainide (Gertz
et al., 1986; Soff and Kadin, 1987; Oliphant and Goddard, 1988;
Feinberg et al., 1990).
In conclusion, we obtained a new tocainide derivative with
greatly enhanced use-dependent block of human skeletal muscle
voltage-gated sodium channels. This improvement was closely
paralleled by an enhanced antimyotonic activity in vivo, while
preliminary toxicological data suggest a good therapeutic index.Tocainide ( M)
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ntage of cell survival after 6 h of incubation with the drug. Each bar represents the
tudent's t-test and effect was considered signiﬁcant for p < 0.05.
M. De Bellis et al. / Neuropharmacology 113 (2017) 206e216 215Although mexiletine is considered as a ﬁrst choice treatment in
both sodium and chloride channel myotonias, 20e40% of the pa-
tients obtain unsatisfactory response (Desaphy et al., 2013c, 2016;
Suetterlin et al., 2015). In this context, To042 appears as a prom-
ising candidate to help increasing therapeutic options in myotonia.
We also hypothesize that To042 may be of interest for other
membrane excitability diseases, such as epilepsy and chronic pain,
and merits attention for further preclinical studies.
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